Photobiomodulation Therapy in the Prevention and Management of Chemotherapy-Induced Alopecia

The registered record

Accession number

NCT05177289

Lead sponsor

Jessa Hospital (other)

Registered condition naming hair loss

Chemotherapy-induced Alopecia

Official title

Evaluating the Feasibility and Efficacy of Photobiomodulation Therapy in the Prevention and Management of Chemotherapy-induced Alopecia: a Randomized Controlled Trial

Interventions

• DeviceTheradome® LH80 pro
• DeviceScalp cooling

Names and types as registered. The sponsors' free-text descriptions of these interventions are not reproduced: they are written by the party with an interest in the result, and reprinting them inside this site's layout would lend them this site's voice.

Design

Study type

interventional

Phase

Not applicable

Allocation

randomized

Masking

single

Primary purpose

prevention

Enrolment

72 participants (estimated)

Sites

1 location in Belgium

What it measures

1. Hair thickness measurement

   Time frame: Baseline

2. Hair thickness measurement

   Time frame: Halfway into their chemotherapy (An average of 6 weeks)

3. Hair thickness measurement

   Time frame: At the final chemotherapy session (An average of 12 weeks)

4. Hair thickness measurement

   Time frame: One month post chemotherapy

5. CTCAE-score

   Time frame: Baseline

6. CTCAE-score

   Time frame: Halfway into their chemotherapy (An average of 6 weeks)

7. CTCAE-score

   Time frame: At the final chemotherapy session (An average of 12 weeks)

8. CTCAE-score

   Time frame: One month post chemotherapy

Primary outcome measures only, as registered. What a trial chose to measure, and when, is the most informative thing about it that is knowable before it reports — a hair-count endpoint at 24 weeks and a patient-satisfaction endpoint at 12 weeks are not the same study.

Who can take part

Sex

female

Age

18 Years

Healthy volunteers

not accepted

A summary of three registered fields, not the eligibility criteria. The full inclusion and exclusion criteria, the recruiting sites and the study contacts are on the registry record, which is the only place they are maintained. This site has no relationship with this trial and cannot refer anyone to it.

Registered dates

Study start

28 February 2022 (actual)

Primary completion

January 2025 (estimated)

Study completion

January 2030 (estimated)

First posted

4 January 2022 (actual)

Last update posted

29 September 2023 (actual)

"Estimated" and "actual" are the registry's own labels: an estimated date is a plan, and plans move. A date is printed at the precision it was registered at: a primary completion registered as 2025-01 is a month, and rendering it as 1 January 2025 would invent a day the sponsor did not register.

Results

This trial has not reported results. ClinicalTrials.gov holds no results record for it. That is the ordinary state of a trial that is running or about to run, and it means there is nothing here to tell you about whether the intervention works — including nothing negative. If this page implied otherwise it would be wrong.

On this site

Guides covering the condition this trial is registered for. They are about published evidence; this page is about a registration, and the two do not overlap.

Chemotherapy Hair Loss: Which Drugs Cause It, What Scalp Cooling Achieves, and the Regrowth Timeline

Where this came from

Read from the ClinicalTrials.gov API on 6 September 2026 and rebuilt into this page without alteration. ClinicalTrials.gov is a service of the U.S. National Library of Medicine and is the authority on this record; where this page and the registry disagree, the registry is right. This page is not affiliated with or endorsed by NLM or NIH, or with the sponsor of this trial.

Open NCT05177289 on ClinicalTrials.gov · All 157 trials in the pipeline